Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

805
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
805

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Higher Medical Urgency Is Associated With Greater Psychosocial Risk Tolerance in Liver Transplant Listing and Selection.

Transplantation·2026
Same author

Access to care affects electronic health record reliability and AI-driven disease prediction.

Nature health·2026
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Blood cancer journal·2026
Same author

Large Language Model Predicts Surgeon Recommendations for Imaging and Surgery for Patients Presenting for Knee and Shoulder Complaints With 70% and 81% Accuracy Using Previsit Questionnaire Responses.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026
Same author

HIV-seq reveals gene expression differences between HIV-transcribing cells from viremic and suppressed people with HIV.

Nature communications·2026
Same journal

Correction: Adeluola et al. Chemoprevention of 4-NQO-Induced Oral Cancer by the Combination of Resveratrol and EGCG: In Vivo, In Silico and In Vitro Studies. <i>Cancers</i> 2026, <i>18</i>, 1098.

Cancers·2026
Same journal

Correction: Peñalver et al. Guidelines for Diagnosis, Treatment, and Follow-Up of Patients with Follicular Lymphoma-Spanish Lymphoma Group (GELTAMO) 2026. <i>Cancers</i> 2026, <i>18</i>, 395.

Cancers·2026
Same journal

Correction: Accorsi Buttini et al. Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50. <i>Cancers</i> 2025, <i>17</i>, 3278.

Cancers·2026
Same journal

Age-Stratified Long-Term Outcomes of Immune Checkpoint Inhibitors for Stage IV Melanoma and NSCLC in The Netherlands: A Population-Based Study.

Cancers·2026
Same journal

Targeting Ferroptosis in Glioblastoma: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Opportunities.

Cancers·2026
Same journal

Neoadjuvant Immunotherapy-Based Treatment Versus Chemotherapy Alone in Resectable Locally Advanced dMMR/MSI-H Gastric Cancer: A Real-World Study with Meta-Analysis.

Cancers·2026
See all related articles

Related Experiment Video

Updated: Feb 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.

Jaysón Davidson1,2, Anupama Kumar3, Ayan Patel2

  • 1Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA 94158, USA.

Cancers
|February 27, 2026
PubMed
Summary
This summary is machine-generated.

Black patients with multiple myeloma (MM) had lower odds of receiving CAR-T therapy. Some eligible patients lacked documented CAR-T therapy discussions, indicating potential disparities in care pathways.

Keywords:
CAR-T eligibilityCAR-T therapyhealthcare disparitiesmultiple myeloma

More Related Videos

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Related Experiment Videos

Last Updated: Feb 28, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

Area of Science:

  • Hematologic Malignancies
  • Immunotherapy

Background:

  • Multiple myeloma (MM) is a significant hematologic malignancy with higher incidence in Black patients.
  • Chimeric antigen receptor T-cell (CAR-T) therapy offers promise but faces access challenges.

Purpose of the Study:

  • To investigate factors associated with CAR-T therapy receipt in MM patients.
  • To examine the impact of disease characteristics, treatment site, and demographics on CAR-T therapy access.

Main Methods:

  • Retrospective cohort study of 12,360 MM patients using electronic health records (2021-2025).
  • Logistic regression analyzed associations between demographics, disease stage, and CAR-T receipt.
  • Zero-shot GPT-4 model assessed CAR-T discussion and eligibility from clinical notes.

Main Results:

  • Only 2.6% of MM patients received CAR-T therapy.
  • Black patients had significantly lower odds of receiving CAR-T therapy compared to White patients (OR 0.33).
  • Disparities in documented CAR-T discussions were observed among eligible patients across racial groups.

Conclusions:

  • CAR-T therapy receipt in MM varies by treatment location and patient race within a large health system.
  • Potential disparities in referral, documentation, or care pathways may influence CAR-T therapy access for certain patient groups.